Background. Most studies on human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (SCC) have been performed on white Americans. Our study examined the incidence of HPV in an African American oropharyngeal SCC cohort and its survival. Methods. African American patients with oropharyngeal SCC in a combined tumor registry were identified. HPV16 testing was performed by polymerase chain reaction (PCR) from DNA extracted from tumor blocks. The p16 staining was performed using standard immunohistochemistry. Results. Forty-four patients were identified for analysis. Seventy-three percent of the tumors were HPV-positive. Only 39% of the patients who were HPV-positive were also p16-positive. Survival between all 3 tumor types, patients who tested HPV-positive/p16, HPV-positive/p16-positive, and HPV-negative/p16-negative was significantly different (p 5 .03). HPV/p16 status was significant on univariate and multivariate analysis. Conclusion. HPV oropharyngeal SCC is strongly present in this African American cohort. Two thirds of the patients who were HPV-positive were p16-negative. Greater study is needed to explain the high p16 negativity among this HPV-positive oropharyngeal SCC African American cohort.
INTRODUCTION
Significantly different rates of overall survival and risk of mortality have been observed in head and neck squamous cell carcinoma (HNSCC) between white Americans and African Americans. 1, 2 The poor survival in African American patients has been attributed to multiple factors, including late stage of diagnosis, a high frequency of recurrences, and second primary tumors. [3] [4] [5] [6] Socioeconomic status, access to care, and insurance status have additionally been shown to be significant contributors to this disparity. 7 In the last decade, a subset of HNSCC caused by the human papillomavirus (HPV), specifically in oropharyngeal squamous cell carcinoma (SCC), has been reported as a distinct molecular and epidemiological disease entity. 8 HPV-associated oropharyngeal SCC are different than traditional patients with HNSCC whose cancers are caused primarily by alcohol and tobacco abuse. Patients with HPV-associated oropharyngeal SCC are usually younger, nonsmokers, and often have specific sexual risk factors. 9 They also have a significantly more favorable prognosis. When compared to non-HPV oropharyngeal SCC, the reported benefit in survival ranges from 25% to 33%. 10, 11 At this time, HPV-associated oropharyngeal SCC is considered a distinct disease from traditional oropharyngeal SCC because of the distinct risk profile and better survival outcomes. Its increased prevalence over time has been well documented, and is projected to exceed the number of cervical cancers by 2020. 12 To date, the majority of studies on HPV-associated oropharyngeal SCC have been reported in white American patients, with limited reports of HPV-associated oropharyngeal SCC in African American cohorts. Given the paucity of data on HPV-associated oropharyngeal SCC in African Americans, we set out to examine the prevalence and outcomes of HPV-associated oropharyngeal SCC in an African American cohort. We hypothesized that, given the observed racial disparity, HPV-associated oropharyngeal SCC was likely less common in African Americans than white Americans. In our analysis, we identified an unexpectedly frequent molecular subtype in this African American cohort, HPV-positive/p16-negative tumors, with demonstrated worse outcomes than HPV-positive/p16-positive oropharyngeal SCC.
MATERIALS AND METHODS
After approval by the institutional review board, a combined database of tumor registries from Temple University Hospital and Fox Chase Cancer Center from 1990 to 2010 was analyzed. All patients with oropharyngeal cancer and whose racial designation was "black" were identified. Available tumor blocks from 1997 to 2010 were retrieved from the archive for analysis. In some cases, no tumor block was available, or available tissue was not representative of tumor tissue. Ninety-five cases were initially identified, and 44 cases had confirmed appropriate paraffin-embedded tissue for analysis with chart data. Parameters from the tumor registry were extracted for analysis. Additional data that were not available in the registry, such as smoking history, including pack-year data, if available, was obtained directly from the patient chart.
Human papillomavirus and p16 tumor testing
For each tumor specimen, 10 unstained slides were obtained of the tumor. DNA was extracted using Archive Pure DNA Extraction Kit (5 Prime, USA). Polymerase chain reaction (PCR) was performed for the presence of HPV16 DNA using the following primers: TTT GGT CTA CAA CCT CCC CCA GGA and TTC TTT AGG TGC TGG AGG TGT ATG. PCR to b-globin was used as an internal control. In samples in which HPV16 PCR results were equivocal or the b-globin control was negative, additional testing using the INNO-LiPA genotyping Extra Amplification and Genotyping Extra kits (Fujireobio Europe N.V., formerly Innogenetics) was performed. Using PCR, this kit identifies a spectrum of HPV genotypes by using a reverse hybridization line probe assay to detect 18 high-risk types: 16, 18, 26, 31, 33, 35, 39, 45 , 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82; 7 low-risk types: 6, 11, 40, 43, 44, 54, and 70; and additional types: 69, 71, and 74. Negative and positive controls (HPV 6) as well as an internal control (HLA-DPB1 gene) to confirm DNA quality and the absence of PCR inhibitors are included in the assay: 25 and 26. Inno-LiPA has been reported to be more sensitive than HPV16 PCR alone. 13 Overall, 10 cases were further analyzed by Inno-LiPA. Three of these cases were initially HPV/p16-positive. In these cases, Inno-LiPA identified HPV16 DNA in all 3 samples, with 1 also containing HPV35. In 5 of these cases, controls for b-globin during HPV16 PCR were negative. Because Inno-LiPA is more sensitive, InnoLiPA was applied in these cases as well. In all 5 cases, the control DNA was positive, with 4 samples detecting HPV16 DNA. One case detected HPV35 alone. Finally, 2 HPV16 PCR samples had a doublet on PCR evaluation. Inno-LiPA evaluation showed both samples to have coinfection with HPV16 and HPV35 infection.
For p16 staining, unstained tumor slides were used for direct immunohistochemical staining. After deparaffinization and rehydration, sections were subjected to heatinduced epitope retrieval by immersion in a 0.01 M citrate buffer (pH 6.0). Endogenous peroxidase activity was blocked for 15 minutes in 3% hydrogen peroxide in methanol. Nonspecific protein binding was blocked with a blocking reagent (Protein Block Serum-Free, DAKO) for 30 minutes at room temperature. The slides were then incubated with p16 primary antibody (E6H4, Ventana, ready-to-use) overnight at 48C in a humidified chamber. Immunodetection was performed with the Dako Envision 1 system. The antigen-antibody immunoreaction was visualized using 3-3 0 -diaminobenzidine as the chromogen. The slides were washed, counterstained with hematoxylin, dehydrated with alcohol, cleared in xylene, and mounted. Anonymous patient samples that were shown previously to express high levels of p16 were used as positive controls. As a negative control, the primary antibody was replaced with mouse immunoglobulin G. The p16 staining results were initially analyzed by the Fox Chase Cancer Center Experimental Histopathology Facility, and scored as positive or negative by 2 experienced pathologists (J.K. and S.P.). Intermediate to strong nuclear and cytoplasmic positivity in 70% to 80% of tumor cells was considered p16-positive. Lack of staining, equivocal, or weak staining up to 20% to 30% of cells was considered negative. Any discrepancy was resolved with a third experienced pathologist.
Statistical analysis
Statistical analysis was performed using SPSS. Univariate and multivariate hazard ratios were calculated using STATA 10.1 (College Park, TX). The Kaplan-Meier plots were used to evaluate survival and the log-rank test was performed to assess statistically significant differences in survival between the HPV-positive and HPV-negative groups. A p value < .05 was considered statistically significant. Follow-up time in months was calculated by subtracting the date of initial diagnosis from the date of last contact for patients who were alive or "date of death" for patients who were dead from all causes, respectively. Kaplan-Meier survival analyses were performed to evaluate overall survival. Both univariate and multivariate Cox proportional hazard models were used to assess the relationship between known risk factors associated with head and neck cancer and outcome. Variables included in both models were sex, age, HPV16/p16 status, and standard of care.
RESULTS
Forty-four cases with clinical data and tumor blocks were available and included in this study for analysis.
Demographics of these patients are summarized in Table  1 . The average and median age at diagnosis was 64 years old. The majority of patients were men (68%). Seventythree percent of patients were confirmed as either current or former smokers. Only 1 patient was a confirmed nonsmoker. Most of the patients were diagnosed with advanced-stage cancers (77%). Most tumors were moderately differentiated (59%). Most patients were treated with concomitant chemoradiotherapy (47%). Patients treated with any surgery were a minority of the group (27%).
Tumors were segregated into 3 subtypes by HPV and p16 status (Table 2) . Thirteen patients (30%) were HPVpositive/p16-positive, whereas 11 patients (25%) were HPV-negative/p16-negative. The majority of tumors were discordant HPV-positive/p16-negative tumors (45%). The p16-negative tumors accounted for the majority (61%) of all HPV-positive tumors. There were no tumors that were HPV-negative/p16-positive. The prevalence of HPVpositive oropharyngeal SCC versus HPV-negative oropharyngeal SCC did not differ over time (data not shown).
The average and median follow-up time for patients still alive was 4.5 and 3.9 years, respectively. KaplanMeier survival analysis was performed for the 3 tumor subtypes (Figure 1) . The 2-year and 5-year overall survival for HPV-positive/p16-positive tumors was 75% and 64.3%, respectively, whereas it was 30% and 10% for HPV-negative/p16-negative tumors. Patients with The 2-year and 5-year overall survival for HPV-positive/p16-negative tumors were intermediate at 50.4% and 17.3%, respectively. These 3 curves were statistically significantly different (p 5 .026). However, the HPV-positive/ p16-negative and HPV-negative/p16-negative survival curves were not significantly different (p 5 .48). On univariate and multivariate analysis, p16 positivity alone was significantly protective, but HPV status alone was not significant. As a combined variable, HPV-positive/p16-positive was significant on univariate and multivariate analysis (Table 3) . TNM stage was not significant for survival.
Neither the year of diagnosis nor insurance type was a significant multivariate factor (data not shown). There were no significant differences in smoking rates or age among the 3 cohorts (data not shown). Of the 3 patients (25%) diagnosed before the age of 50, all patients were HPV-positive, but only 4 patients (44%) were also p16-positive. The single confirmed nonsmoker had an HPVpositive/p16-positive tumor.
DISCUSSION
The prevalence and outcomes of HPV-associated oropharyngeal SCC in African American populations has not been extensively studied. Only a few articles have been published that examine HPV-associated oropharyngeal SCC in African American cohorts.
12,14-16 Settle et al 15 evaluated African American patients with oropharyngeal SCC from the TAX324 trial. Although 34% of white American patients in this study were diagnosed with HPV-associated oropharyngeal SCC, only 1 patient (4%) was HPV-associated in the African American group. In their oropharyngeal SCC subset analysis, they found a significant difference in overall survival of 69.4 months in white Americans versus 25.2 months in African Americans (p 5 .0006). They concluded that the low rate of HPV-associated oropharyngeal SCC in the African American cohort likely accounted for the observed poor outcomes. Chernock et al 14 also evaluated the differences in racial HPV-associated oropharyngeal SCC rates and outcomes of white Americans and African Americans. In this study of 26 African American patients, only 9 (34%) were diagnosed with p16-positive oropharyngeal SCC. In contrast, 83% of the 148 white American patients were p16-positive (p < .001). The authors noted a significant difference in both prevalence and disease-specific survival of HPV-associated oropharyngeal SCC between the white American and African American cohorts (p < .001). In a third study examining 49 African American patients, Worsham et al 16 found a lower rate of HPV-associated oropharyngeal SCC in African Americans (29%) versus white Americans (71%), with HPV-negative oropharyngeal SCC African American patients having the worst outcomes. The p16 data were not included in this study analysis. Finally, Isayeva et al 12 evaluated HPV and p16 status in 30 African American patients. They also showed a lower rate of HPV-positive and p16-positive tumors in their African American cohort with also worse outcomes than white Americans.
Because of differences in how these 4 studies were performed, drawing conclusions has been difficult. Each study used a different method of HPV identification, and only 2 of 4 studies reported both p16 status and HPV status. All studies have small cohorts ranging in 26 to 49 patients. Not all studies reported smoking status. Despite this, a few common themes emerge. All studies demonstrate a lower rate of HPV-associated oropharyngeal SCC in the African American cohort compared with the white American cohort. In addition, African American patients diagnosed with HPV-negative oropharyngeal SCC consistently had the worst outcome across both race and HPV tumor types.
Our study is the largest study to examine both HPV and p16 status in an African American cohort. Oropharyngeal SCC tumors in our African American smoking cohort stratified into 3 molecular subtypes. True HPV-associated oropharyngeal SCC, defined as HPV-positive/p16-positive tumors, had the most favorable outcome with a 5-year overall survival estimate of 64%. Non-HPV-associated oropharyngeal SCC tumors and HPV-negative/p16-negative tumors had the worst outcome with 10% 5-year overall survival. Most interestingly, discordant HPV-positive/p16-negative tumors were the most common tumor type in our African American cohort, and had outcomes similar to the HPV-negative/p16-negative cohort. The identification of a high number of discordant tumors with demonstrated poor outcome is a unique finding of our study.
HPV-positive/p16-negative negative tumors have been previously reported. In their study, Weinberger et al 17 initially separated oropharyngeal SCC into 3 distinct classes. HPV-negative/p16-negative (class I) are classic tobacco/ alcohol-related tumors and have the worst prognosis. HPVpositive/p16-positive (class III) represent canonical HPVassociated oropharyngeal SCC tumors and have the most favorable prognosis. HPV-positive/p16-negative (class II) discordant tumors were thought to arise in a background of patients with tobacco/alcohol use who develop p16 loss and subsequently experience a high-risk HPV infection. A subsequent study also by Weinberger et al 18 examining white American and African American tumors by HPV and p16 status showed that although all 3 types were present in a white American cohort, only class I (HPV-negative/p16-negative) and class II (HPV-positive/p16-negative) tumors were seen in a small African American study cohort. HPV-positive/p16-positive tumors were not observed in this group. They concluded that the absence of HPV-positive/p16-positive tumors in their study could explain white American versus African American oropharyngeal SCC disparities.
Subsequent studies have clearly shown that that HPVpositive/p16-positive tumors are observed in African Americans with associated favorable outcomes. 12, 14, 15, 19 However, these tumors make up a minority of African American cohorts, approximately 30% in comparison to 60% to 70% of tumors in white American cohorts.
14 Our study shows a similar 30% rate of HPV-positive/p16-positive tumors.
HPV-positive/p16-negative discordant tumors remain an uncommon finding among white American cohorts but are more common in African American cohorts. Both Isayeva et al 12 and Chernock et al 14 showed that HPVpositive/p16-negative tumors were present in their white American cohorts, but represented only 4% to 5% of white American oropharyngeal SCCs. By contrast, Isayeva et al 12 noted that 25% of their African American oropharyngeal SCC cohort was HPV-positive/p16-negative. In our data, 45% of the total African American oropharyngeal SCC cohort was discordant HPV-positive/p16-negative tumors. The reasons for a higher rate in our cohort are unclear. Isayeva et al 12 used RNA PCR to determine HPV status, whereas our study used HPV16 PCR, and both are accepted as effective in identifying HPV-positive tumors. Additionally, our study was mostly African American smokers; data are not available to compare our data to other studies regarding smoking status. Overall, our study suggests that discordant HPV-positive/ p16-negative tumors are unusually common in African American cohorts.
The perceived low rate of discordant tumors in white American populations may be confounded by underreporting. Because some studies use p16 status alone as a surrogate for HPV-associated oropharyngeal SCC, HPVpositive/p16-negative discordant tumors may be grouped with other HPV-negative/p16-negative tumors and would not be identified. In addition, because some studies use HPV in situ hybridization as the technique for HPV identification, because in situ hybridization is known be less accurate than other methods like PCR, the rate of HPVpositive/p16-negative tumors may be underreported. 20 We speculate that HPV is unlikely to be a passenger virus in these p16-negative tumors. There was no difference seen in survival between HPV-positive/p16-negative and HPVnegative/p16-negative tumors (p 5 .48). However, our study may be underpowered to identify a survival difference. We do note that all patients diagnosed under the age of 50 were HPV-positive, with only 4 of the 11 being p16-positive. If a passenger virus, one would expect HPV to be evenly distributed across tumors over the age spectrum. Although there was no difference in age between HPV-positive versus HPV-negative cohorts, it is interesting that all 11 patients under the age of 50 were HPV-positive. The cause of discordant tumor development is unknown. Possibilities include behavioral factors, smoking prevalence, or genetic factors that preferentially dispose African American cohorts. The pathogenesis, epidemiology, and evaluation of outcomes of these discordant tumors warrant further investigation.
There were a few limitations to our study. Because of limitations in clinical records, disease-specific outcomes were unable to be obtained and only overall survival could be reported. The very low 5-year overall survival in both HPV-positive/p16-negative and HPV-negative/ p16-negative disease may reflect other competing mortalities in our population. TNM stage was not significant for survival on multivariate analysis. This may be due to the relatively few early-stage tumors and that advanced-stage cancers were 80% of the evaluated cohort. Future analysis should control for comorbidities within the different treatment arms to ensure no bias by competing mortalities. An additional limitation is lack of a direct control group for comparison. A control white American oropharynx population with annotated HPV and p16 data would lend strong context to our findings and add to this study. The rate of discordant tumors in this population would be an excellent comparison. As mentioned previously, published white American data suggest a low discordant tumor rate. We aim to explore this possibility in future research. Finally, the 44 identified patients in this study is the second largest African American oropharyngeal SCC cohort that we have identified in the literature, but is still a limited number. Future studies with a larger cohort for analysis may strengthen our conclusions and findings.
Published literature and the lay press refer to HPVassociated oropharyngeal SCC as a distinct clinical entity on the rise. Our study, and similar studies, suggests that not all HPV-associated oropharyngeal SCC is the same. The distinct incidence profile and better survival is limited to HPV-associated oropharyngeal SCC that is also p16-positive. Oropharyngeal SCC that has detectable HPV DNA, but is p16-negative in our study and other studies, still has a poor prognosis. The definition of "HPVassociated oropharyngeal SCC" needs clarification and we submit that p16 positivity must also be part of the definition; the presence of HPV DNA alone through any testing method is an inadequate definition for this entity. Future clinical trials on this entity should include p16 status as inclusion criteria. Discordant tumors, as we have identified here in a black cohort, suggest that further study is needed to understand HPV-associated oropharyngeal SCC.
CONCLUSIONS
Our study demonstrates that HPV is present in the majority of oropharyngeal SCC within an African American smoking cohort. However, most of these tumors are discordant HPV-positive/p16-negative with poorer outcomes than HPV-positive/p16-positive tumors. Although highly prevalent in this African American oropharyngeal SCC cohort, its presence is rarely seen in reported white American cohorts. More study is needed to understand the pathogenesis, epidemiology, and outcomes of these discordant tumors.
